NOSIUM AB (publ) ("NOSIUM" or the "Company"), to be renamed Medicortex International AB (publ), has received conditional approval for continued listing on NGM Growth Market.
The Company is currently under observation status on NGM Growth Market following its announcement of its intention to carry out a reverse acquisition of Medicortex Finland Oyj. The reverse acquisition (the "Transaction") constitutes a significant change in the Company's operations pursuant to Section 3.2 of the Nordic Growth Market ("NGM") Rulebook for NGM Growth Market. Accordingly, the Company has undergone a new listing review and has now received conditional approval for continued listing on NGM Growth Market.
Medicortex Finland Oyj is a Finnish medical technology company developing non-invasive diagnostic tests for traumatic brain injuries (TBI). The tests are based on biomarkers found in saliva and urine, enabling point-of-care diagnostics in settings such as emergency departments, sports arenas, and field environments.
The listing decision is conditional upon (i) the Company completing the Transaction and (ii) no new information arising that would affect the Company's fulfilment of the listing requirements.
The Company's observation status will remain in place until all conditions for the listing decision have been fulfilled.
For more information about NOSIUM, please visit www.nosium.com.
For further information, please contact:
Listing Department, Nordic Growth Market
notering@ngm.se
Carl-Henrik Nordberg, Head of Equity, Nordic Growth Market
carl-henrik.nordberg@ngm.se